4 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Terminated 4 |
Follow Amyloidosis: new trials by email Literature Review of Amyloidosis trials Research Report on Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis Birtamimab, Placebo, Standard of Care Chemotherapy - Light Chain (AL) Amyloidosis | Phase 3 | Terminated | Prothena Biosciences Ltd. | 208 | 2021-08-30 | 2025-12-16 |
| Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib Bortezomib, Melphalan, Neupogen - AL Amyloidosis | Phase 3 | Terminated | Boston Medical Center | 3 | 2015-06-01 | 2018-09-10 |
| The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis NEOD001, Placebo - Primary Systemic (AL) Amyloidosis | Phase 3 | Terminated | Prothena Biosciences Ltd. | 260 | 2015-02-01 | 2023-11-14 |
| Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis IXAZOMIB, Dexamethasone, Melphalan - Relapsed or Refractory Systemic Light Chain Amyloidosis | Phase 3 | Terminated | Millennium Pharmaceuticals, Inc. | 177 | 2012-12-26 | 2025-09-02 |
Immunoglobulin Light-chain Amyloidosis (2) · Recurrence (1)
Metabolic Diseases (4) · Nutritional and Metabolic Diseases (4) · Proteostasis Deficiencies (4) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Plasma Cell (2) · Paraproteinemias (2) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Melphalan (2) · birtamimab (2) · Blood Component Removal (1) · Bortezomib (1) · Cyclophosphamide (1) · Dexamethasone (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Lenalidomide (1) · Thalidomide (1) · ixazomib (1)
Prothena Biosciences Ltd. (2) · Boston Medical Center (1) · Millennium Pharmaceuticals, Inc. (1)
United States (4) · Australia (3) · Canada (3) · Denmark (3) · France (3) · Germany (3) · Greece (3) · Israel (3) · Italy (3) · Netherlands (3) · Spain (3) · United Kingdom (3) · Austria (2) · Belgium (2) · Czechia (2)